More in depth analysis in arriving on Opdivo and its impact on SIRT. The accelerated FDA approval immediately brings Opdivo to second line for HCC off crazy PhaseI-II data. Opdivo has a response rate of 15-20% versus sorafenib at 2%. PhaseIII reports next year and the oncology space is expecting a homerun which will bring it to first line.
People are expecting SIRT to be pushed back down the treatment waterfall and eventually they will have to start a new batch of clinical trials targeting SIRT +/vs Opdivo.
- Forums
- ASX - By Stock
- wats going on ???
More in depth analysis in arriving on Opdivo and its impact on...
-
-
- There are more pages in this discussion • 23 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add SRX (ASX) to my watchlist
|
|||||
Last
18.0¢ |
Change
0.000(0.00%) |
Mkt cap ! $76.40M |
Open | High | Low | Value | Volume |
17.5¢ | 18.0¢ | 17.5¢ | $61.98K | 351.9K |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
8 | 11238850 | 17.5¢ |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
18.0¢ | 1266857 | 36 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
8 | 11238850 | 0.175 |
1 | 164705 | 0.170 |
1 | 18187 | 0.165 |
1 | 2577 | 0.097 |
1 | 4000 | 0.075 |
Price($) | Vol. | No. |
---|---|---|
0.180 | 1246997 | 29 |
0.185 | 5000 | 1 |
0.190 | 315669 | 6 |
0.195 | 20478 | 2 |
0.200 | 181416 | 6 |
Last trade - 16.10pm 06/09/2024 (20 minute delay) ? |
Featured News
SRX (ASX) Chart |